文献速递妇科

HDAC10作为卵巢癌潜在治疗靶点

HDAC10 as a potential therapeutic target in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-01-07

研究分析HDAC10在BRCA1缺失卵巢癌细胞DNA损伤反应中的功能,并评估广谱HDAC抑制剂在原代卵巢癌细胞中的作用;TCGA数据显示HDAC10深度缺失见于5-10%卵巢癌肿瘤,低HDAC10 mRNA水平与铂类敏感相关,抑制或敲低HDAC10可致DNA修复能力降低并增敏铂类治疗,作者认为抑制HDAC10可能增强铂类疗效。

要点

  • TCGA数据显示HDAC10深度缺失见于5-10%卵巢癌肿瘤。
  • TCGA数据中低HDAC10 mRNA水平与肿瘤铂类敏感相关。
  • BRCA1缺失卵巢癌细胞中HDAC10抑制或敲低降低DNA修复能力并增敏铂类治疗。

核心结论

  • 作者认为抑制HDAC10可能增强铂类治疗对卵巢肿瘤的疗效。

研究设计与样本

  • 将卵巢癌肿瘤大型DNA测序数据集的信息学分析与原代及已建立细胞系的组织培养试验相结合,检测抑制或敲低HDAC10活性后的铂类治疗敏感性。

主要发现

  • 使用癌症基因组图谱(TCGA)数据集发现HDAC10深度缺失见于5-10%的卵巢癌肿瘤。
  • TCGA数据中低HDAC10 mRNA水平与肿瘤铂类敏感相关。
  • BRCA1缺失卵巢癌细胞系的细胞增殖与DNA损伤试验显示DNA修复能力降低并增敏铂类治疗。
  • 原代卵巢癌细胞经HDAC抑制剂处理后同样显示对铂类治疗增敏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We analyzed histone deacetylase 10 (HDAC10) for function in the context of the DNA damage response in BRCA1-null ovarian cancer cells as well as evaluated the potential of general HDAC inhibitors in primary ovarian carcinoma cells. HDAC10 had previously been shown to be highly stimulatory to the process of homology directed repair in HeLa cells, and in this study we investigated whether HDAC10 could impact in vitro the response to anticancer therapies. We hypothesized that the loss of HDAC10 would sensitize cells to platinum therapy. METHODS: We combined informatics analysis of large DNA sequencing datasets from ovarian cancer tumors with tissue culture based assays of primary and established cell lines to test for sensitivity to platinum therapy if HDAC10 activity was inhibited or depleted. RESULTS: Using The Cancer Genome Atlas (TCGA) dataset, we found that deep deletions in HDAC10 occurred in 5-10% of ovarian cancer tumors. From the TCGA data we found that low HDAC10 mRNA levels correlated with platinum sensitivity of the tumors. Cell proliferation and DNA damage assays in a BRCA1-null ovarian carcinoma cell line demonstrated reduced DNA repair capacity and sensitization of platinum therapy. Similarly, primary ovarian carcinoma cells demonstrated a sensitization to platinum therapies when treated with HDAC inhibitors. CONCLUSIONS: From the results of this study, we suggest that the inhibition of HDAC10 may potentiate the effects of platinum therapies in ovarian tumors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Islam MM, Banerjee T, Packard CZ, et al. HDAC10 as a potential therapeutic target in ovarian cancer. Gynecol Oncol. 2017. PMID: 28073598. doi:10.1016/j.ygyno.2017.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。